Keylights Biotechnology Co., Ltd., a leading in vitro diagnostic (IVD) instruments manufacturer headquartered in Shenzhen, has reportedly secured nearly RMB 100 million (USD 14 million) in a Series B financing round. The round was led by Luxin Venture Capital, with participation from Hanchi Venture Capital. The funds raised will be directed towards the commercial promotion of a comprehensive suite of IVD instruments, encompassing chemiluminescence, immunofluorescence, flow cytometry, and mass spectrometry pre-treatment technologies.
Established in 2021, Keylights Bio has rapidly expanded its business reach to cover over 800 Class 3A hospitals, top-tier third-party medical testing institutions, and more than 2000 additional medical facilities. The company’s products have been installed in various countries, including Germany, France, Spain, the United States, Brazil, India, Peru, Nepal, and others, demonstrating its global footprint and market penetration.- Flcube.com
